BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Mirada Medical Supplies Deformable Fusion Technology for Varian, Inc. (VARI)'s SmartAdapt, Presents Validation Study at ASTRO


9/29/2011 8:27:00 AM

OXFORD, UNITED KINGDOM--(Marketwire - September 29, 2011) - Mirada Medical has integrated its multi-modal Deformable Fusion technology into Varian's SmartAdapt application and will present a study assessing the efficacy of the technology for MR to CT deformable registration at the annual meeting of the American Society for Radiation Oncology (ASTRO) in Miami, Florida.

Mirada will also be showcasing a new range of software planning tools in their exhibit (Booth #1257) that incorporate its fusion technologies to support: dose warping, dose summation, atlas based auto-contouring, deformable fusion of multi-sequence MR, PET and SPECT and single click contour warping to support adaptive re-planning.

"We are proud that our industry leading registration technology has been incorporated into Varian's SmartAdapt. The validation study demonstrates that diagnostic or treatment position MR can be reliably aligned to CT planning images," says Dr. Timor Kadir, Mirada Chief Science and Technology Officer. "This technology brings the benefit of MRI's unrivalled soft tissue differentiation into conventional CT based planning."

Dr. Mark Gooding, senior scientist at Mirada, will present the study and poster presentation (#3262) at ASTRO. The study was chosen from a record breaking 2,437 abstracts submitted for review to be presented. ASTRO is the largest gathering of radiation oncology specialists in the world.

The study, titled "Assessing the quality of deformable CT-MR registration for the purpose of multi-modal radiotherapy planning," examines the performance of Mirada's multi-modal deformable registration algorithm for the fusion of head and neck, prostate and cervical diagnostic MR scans to CT planning volumes. Performance was assessed by experts in radiation oncology from four independent clinical institutions and quantitative errors were also measured using landmarks. In all cases, deformable registration significantly improved the alignment between MR and planning CT, approximately halving the registration error compared to conventional rigid alignment. The clinical experts' assessment concluded that the results required minimal intervention prior to use in multi-modal contouring.

About Mirada Medical
Mirada Medical is an internationally recognised brand in advanced medical imaging. The company develops high value clinical software applications, which are used across diagnostic radiology, nuclear medicine, radiation oncology, tumor board and elsewhere.

Mirada specializes in simplifying technically complex image processing tasks, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention.

Mirada was originally spun out of the University of Oxford. The company's technologies are, to this day, developed by a team of dedicated engineers and world-renowned scientists working out of Oxford, England.

Mirada's products have been designed to ease the deployment of these powerful technologies into any hospital or imaging center workflow. Mirada's applications can be delivered using thin client or cloud based architectures, or licensed on a floating or per workstation basis. Most recently, Mirada has focused on the development of disease specific solutions for use across departments working with patients to fight cancer. In particular, Mirada's powerful image registration technologies have been tuned to the needs of radiation oncology, and quantification technologies have been redefined to optimize support for standard protocols such as RECIST and PERCIST. In addition, powerful imaging solutions have been introduced to support better collaborative working, in particular in the context of a rich web-based viewer for referring physicians and a robust solution for presentation of images at multidisciplinary meetings such as tumor board.

Mirada Medical, Mirada XD3 and Casemeeting are all trademarks of Mirada Medical Ltd.

For more information, visit www.mirada-medical.com

PDF of release: http://hugin.info/143183/R/1550717/477469.pdf


For more information, please contact:

Mirada Medical
US/Worldwide:
Robert
tel: (440) 591-8638
Insource Communications
rripley@insourceinc.com
enquiries@mirada-medical.com
www.mirada-medical.com

UK Office:
Oxford Center for Innovation
New Road, Oxford
OX1 1BY
United Kingdom
Tel: +44(0)1865 261410


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->